Local Antibiotic Delivery Systems in Diabetic Foot Osteomyelitis: A Brief Review

Christos Chatzipapas¹, Makrina Karaglani¹, Nikolaos Papanas², Konstantinos Tilkeridis¹, Georgios I. Drosos¹

¹ Department of Orthopaedic Surgery, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece. ² Diabetes Centre - Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece. Address correspondence to: Nikolaos Papanas, e-mail: papanasnikos@yahoo.gr

Abstract

Diabetic foot osteomyelitis (DFO) is a severe, difficult to treat infection. Local antibiotic delivery has been studied as a potential therapeutic adjunct following surgery for DFO. This review aims to summarize the evidence on local antibiotic delivery systems in DFO. PubMed database was searched up to March 2020. Overall, 16 studies were identified and included: 3 randomized controlled trials (RCTs), 3 retrospective studies (RSs), and 10 case series. In the RCTs, gentamicin-impregnated collagen sponges significantly improved clinical healing rates and slightly improved duration of hospitalization. In the RSs, antibiotic-impregnated calcium sulfate beads non-significantly improved all healing parameters, but did not reduce post-operative amputation rates or time of healing. The majority of case series used calcium sulfate beads, achieving adequate rates of healing and eradication of infection. In conclusion, evidence for add-on local antibiotic delivery in DFO is still limited; more data are needed to assess this therapeutic measure.

Keywords: diabetic foot osteomyelitis · local antibiotic delivery · PMMA · calcium sulfate

1. Introduction

Diabetes mellitus increases the risk of foot infections, some cases of which progress to diabetic foot osteomyelitis (DFO) [1, 2]. Foot deformity, peripheral neuropathy, peripheral arterial disease, and minor injury increase the risk of diabetic foot lesions [2-5]. The development of biofilms in chronic wounds represents an additional challenge, since they protect pathogens from removal by host immunity and systemically administered antibiotics [6].

Management of DFO may be surgical or medical, depending on patient characteristics [7]. Surgery is especially useful in the event of pus, sequestrum, gangrene, or antibiotic-resistant bacteria [8]. Instead of amputation, debridement offers the advantage of removing necrotic while preserving healthy bones and tissues [9]. This approach is sometimes accompanied by local antibiotic delivery [3].

Local antibiotics offer the following advantages: higher local antibiotic concentration, longer duration, and fewer side effects [3]. At the same time, they act as a bone substitute that fills the dead space caused by bone resection [10]. Polymethylmethacrylate (PMMA) beads are the major representative of non-biodegradable carriers [11]. Antibiotic release from PMMA beads is initially high during the first 48-72 hours, but quickly falls to lower levels, and may elute for weeks or even years [11]. Disadvantages include the high temperature it produces and the surgical removal of the beads required upon completion of drug release [12, 13].

During the last 2 decades, biodegradable carriers have been developed: proteins (collagen, gelatin, thrombin etc.), synthetic polymers, grafts, and substitutes (calcium sulfate or phosphate) [14]. These act as a matrix for new bone growth. During their degradation, additional release of antibiotics occurs, prolonging their action and preventing biofilm formation on their surface [15].

The aim of this brief review is to summarize the evidence on add-on local antibiotic delivery in the surgical management of DFO.
2. Search strategy

We performed a search in the PubMed database for studies published up to December 2020 on the management of patients with DFO using an implantable antibiotic delivery system. We excluded case reports, case series with fewer than 5 patients, in vitro studies, reviews, comments, letters, and studies on other locations of osteomyelitis. Studies in which >10% of patients did not have diabetes were excluded unless the results for these patients were presented separately. Only publications in the English language were included.

Parameters evaluated included healing rates, time, and complications, such as further surgical interventions, amputation rates, and mortality. Clinical presentation, laboratory investigation, radiological evaluation, antibiotic therapy, duration of symptoms, previous surgical procedures, and comorbidities were also recorded.

3. Results

In total, 16 studies were included (Table 1): 3 randomized controlled trials (RCTs) [15-17], 3 retrospective studies (RSs) [18-20], and 10 case series [3, 21-29]. Overall, 9 studies described the use of calcium sulphate tablets/beads, 4 studies assessed the use of gentamicin-impregnated collagen sponges, and one study used either calcium sulfate tablets or gentamicin-impregnated sponges. Four studies used PMMA for definitive treatment, and one study used PMMA as part of a two-stage procedure.

3.1 Randomized controlled trials

Lipsky et al. randomized 56 patients with moderately infected diabetic foot ulcers in a 2:1 ratio into 2 groups, one with and the other without the use of a gentamicin-collagen sponge in addition to standard care for up to 28 days [15]. Significantly higher rates of clinical cure and eradication of pathogens were achieved in the gentamicin-collagen sponge group [15]. Safety data were similar between the 2 groups.

Varga et al. investigated the efficacy of a gentamicin-collagen sponge application into wounds after minor amputation for non-healing ulcers with DFO [16]. Fifty diabetes patients were randomized to the add-on gentamicin sponge or usual care group. All patients received systemic antibiotics according to their antibiotic profile. In the gentamicin sponge group, wound healing duration was significantly shortened by almost 2 weeks. No differences were observed between the groups in length of hospitalization or number of revisions for wound breakdown or subsequent amputations.

Uçkay et al. continued their initial trial re-examining the potential benefits of gentamicin-collagen sponges in a larger RTC of 88 patients with DFO and prolonged follow-up [17]. There was no difference in clinical cure rates in favor of the gentamicin-sponge. However, a small trend towards faster healing was noted in the gentamicin-collagen sponge group. Similar to the other studies, local antibiotic delivery was not associated with safety concerns.

3.2 Retrospective studies

Krause et al. assessed the effect of local tobramycin-impregnated calcium sulfate beads in addition to standard treatment after transmetatarsal amputation in diabetes patients with non-healing forefoot full-thickness ulceration with DFO or skin necrosis [18]. In total, data from 65 amputations were reviewed, including 49 cases in the beads group and 16 cases in the group without beads. Wound breakdown rates were significantly lower in the beads group. In this group, there was also a non-significant reduction in time of healing. There were no differences between the groups in length of hospitalization and need for ipsilateral second transtibial amputation.

Qin et al. compared infected bone resection combined with adjuvant antibiotic-impregnated calcium sulfate vs. infected bone resection alone for the treatment of DFO in 46 patients [19]. Antibiotic-impregnated calcium sulfate prevented the recurrence of DFO, but showed no significant improvement in healing rates, post-operative amputation rate, and time of healing.

In the most recent retrospective study, Chatzipapas et al. recruited 25 patients with forefoot and calcaneal DFO who were divided into 3 groups [20]. Healing rates were 100% in the PMMA group (surgical debridement in combination with the local application of antibiotic-loaded PMMA beads), 87.5% in the control group (surgical debridement in combination with the local application of hydroxypatite and calcium sulfate beads), and 87.5% in the control group (surgical debridement only) [20].

3.3 Case series

Roukis et al. studied 16 patients (15 diabetes) with medical comorbidities and offered two-stage reconstruction with a surgical skin flap of full-thickness foot ulcers using a V-Y technique for patients with high risk of wound breakdown [21]. Antibiotic-impregnated PMMA spacers were used in all first-stage procedures. After 3 days, a second-stage procedure was performed, involving further debridement, V-Y flap cover, and filling of bone defects with either bone graft combined with platelet-rich plasma or with antibiotic-impregnated PMMA. This treatment resulted in
Table 1. Main findings from the included studies on local antibiotic treatment in foot infections and diabetic foot osteomyelitis (DFU)

| Study Design | Design | Number of patients | Intervention | Follow-up | Results | Complications |
|-------------|--------|-------------------|--------------|-----------|---------|---------------|
| Lipsky <em>et al</em>, 2012 | RCT | 56 patients with moderately infected diabetic foot ulcers, randomized into treatment (n=38) and control (n=18) group. | Daily topical application of gentamicin-impregnated collagen sponges combined with systemic antibiotics compared with systemic antibiotic therapy alone. Standard diabetic wound management, including sharp surgical debridement at each visit. | 14 to 28 days of treatment plus 2 weeks after treatment was discontinued. | The treatment group had a significantly higher proportion of patients with a clinical cure than the control group. | The most common adverse events occurring in at least two patients per group were infections with skin ulcers, tinea pedis, and increased blood creatinine concentration. |
| Varga <em>et al</em>, 2012 | RCT | 50 DFU patients were randomized into treatment (n=25) and control (n=25) group. | Gentamicin-impregnated collagen sponges peri-operatively in comparison with minor amputations without sponges. Systemic antibiotics were administered to both groups. | Indications for amputation were non-healing ulceration (more than 6 weeks) | There was no significant difference in hospital stay and further surgery between the groups. Wound healing duration in the treatment group was significantly better than in the control group. | Three re-amputations (1 major and 2 minor) were necessary for non-healing wounds in the treatment group. In the control group, 4 minor re-amputations were performed. |
| Uckay <em>et al</em>, 2019 | RCT | 88 DFU patients were randomized into treatment (n=45) and control (n=43) group. | Gentamicin-impregnated collagen sponges with systemic antibiotic vs. systemic antibiotics alone; surgical debridement if there was a clinical need to remove necrosis or to drain an abscess. | 14-28 days of treatment plus 10 days after treatment was discontinued. | 73% showed total clinical cure, 15% significant improvement, and 52% showed total eradication of all pathogens. Regarding the final clinical cure, there was no difference in favor of the gentamicin-sponge. | There was a tendency towards more rapid healing in the gentamicin-sponge group. Gentamicin-sponges were very well tolerated, without any attributed adverse events. |
| Krause <em>et al</em>, 2014 | RCT | 50 DFU patients divided into Gemini (n=25) and control (n=25) group. | Application of tobramycin-impregnated calcium sulfate beads in addition to transtibial amputation and standard treatment vs. no beads. | 17 patients died and 3 were lost to follow-up after 29 months. | The beads group showed a lower rate for wound breakdown and further surgery, but there was no difference in length of hospital stay or rate of conversion to below-the-knee amputation. | Prolonged postoperative leakage in the CS group was the most common complication. |
| Qin <em>et al</em>, 2019 | RCT | 88 DFU patients divided into treatment (n=49) and control (n=39) group. | Vancomycin and/or gentamicin-impregnated calcium sulfate beads after bone resection vs. bone resection alone. Systemic antibiotics in both groups. | At least 12 months | Local antibiotics prevented the recurrence of DFO, but did not improve the healing rate, reduce the postoperative amputation rate, or shorten time to healing. | Prolonged postoperative leakage in the CS group was the most common complication. |
| Chatzipapas <em>et al</em>, 2020 | RCT | 25 patients with foot and calcaneal DFU were divided into 3 groups: PMMA (n=9), H/CSF (n=8), and control (n=8). | Gentamicin-impregnated PMMA or H/CSF beads or nothing plus minor surgery. Concomitant antibiotics (first intravenously, later orally). | At least 12 months | All healing parameters were improved in both local antibiotic groups, but they did not reach statistical significance. | Recurrence of DFO in two patients, one in the PMMA group and one control. The latter underwent amputation. |
| Krause <em>et al</em>, 2009 | CS | 16 patients (15 had diabetes) with forefoot full-thickness soft tissue defects. | Primary upper excision, surgical debridement, antibiotic-impregnated PMMA, and immobilization. 3 days later, 2nd debridement, V-Y fasciocutaneous advancement flap coverage. Osseous defects were filled with either allogeneic bone graft impregnated with PRP or a permanent antibiotic-impregnated PMMA spacer. | 15±9 months (range 4-34) | All but 4 flaps healed primarily, with each developing marginal dehiscence which healed with local wound care measures. | Two deep infections occurred despite the healing of the flap, which necessitated transmetatarsal amputation with split-thickness skin graft coverage. |
| Author(s)                     | Year | Case Series Size | Description                                                                 | Treatment                                                                                   | Results                                                                                                                                 |
|------------------------------|------|------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Gauland, Peled               | 2011 | 337              | Lower extremity osteomyelitis                                                  | Locally implanted vancomycin- and gentamicin-impregnated calcium sulfate tablets in the surgical debridement site. | Max of 5 years of follow-up, 279 of 323 patients were clinically healed without the use of intravenous antibiotics. 30 patients required amputation, 12 of which were digital amputations, 2 ray amputations, and 6 below-knee amputations. |
| Melamed and Walsh and Yates  | 2012 | 23               | Lower extremity and associated severe infection of forefoot joints in 20 consecutive patients. | Gentamicin/vancomycin-impregnated calcium sulfate and extensive meticulos debridement.     | 21 cases healed and two required toe amputation. The spacer was left permanently in 10 patients, removed with arthrodesis in six, and removed without arthrodesis in five. |
| Melamed and Peled            | 2012 | 10               | Lower extremity osteomyelitis                                                  | Calcium sulfate spacer in the surgical debridement site.                                    | Over 3 years, 5/7 diabetes patients healed at a mean of 64 days. 2/7 diabetes patients required transfibial amputation after multiple debridements. |
| Walsh and Yates              | 2013 | 20               | Lower extremity osteomyelitis                                                  | Minimal surgical intervention plus highly purified synthetic calcium sulfate impregnated with vancomycin and gentamicin locally. | Over 18 months, all patients healed with a median period of 5 weeks and no recurrence. No adverse reactions. |
| Jogia et al.                 | 2015 | 8                | Chronic metatarsal and calcaneal osteomyelitis                                | Gentamicin-impregnated PMMA or calcium sulfate/carbonate beads locally administered. Concomitant antibiotics (first intravenously, later orally). | 12 months, in all patients, DFO was successfully treated. Wound healing was seen in 6 patients. One patient developed new ulceration in the ipsilateral and contralateral foot within 24 months. |
| Dalla Paola et al.           | 2015 | 28               | Forefoot DFO                                                                   | After surgical debridement with removal of the infected bone, vancomycin/gentamicin-impregnated bone cement was inserted and the treated area was stabilized with an external fixator. | 12±7 months, in 24 patients, no recurrence of ulceration and no transfer ulceration, shoe fit problems, or gait abnormalities were detected. Four patients developed relapse of the ulceration. One of them underwent a percutaneous revascularization procedure and transfibular amputation. |
| Elmarsafi et al.             | 2017 | 30               | Foot osteomyelitis                                                             | PMMA and gentamicin/vancomycin-impregnated cement spacers placed into a previously infected foot after surgical excisional debridement. | Average 52 months; range 12 to 111 months, 20 successful spacers. Of the remaining 10 patients, 8 underwent eventual ipsilateral partial foot amputation. No major amputations had been required on the ipsilateral side. 3 patients underwent contralateral below-the-knee amputations. |
| Drampalos et al.             | 2018 | 12               | Chronic calcaneal osteomyelitis                                                | A gentamicin-impregnated synthetic mixture of calcium sulfate and hydroxyapatite injected in multiple tunnels. Systemic antibiotics for 8-12 weeks. | Average 16 weeks; range 12-18 months, infection was eradicated and the wound healed in all 12 patients with a single-stage procedure. In 6 patients, the wound was closed primarily. VAC needed in 6 patients; one underwent a reverse sural flap procedure at a second stage. |
| Niazi et al.                 | 2019 | 70               | DFO patients                                                                  | Gentamicin-impregnated calcium sulfate/hydroxyapatite bio-composite along with surgical debridement and systemic antibiotics. | Average 10 months; range 4-26 months, infection was eradicated in 63 patients with an average time to ulcer healing of 12 weeks. No additional recurrence of infection was seen in any patient and no local or systemic side effects presented in any patients during treatment. Seven patients were not cured and required further treatment. Five patients had a below-knee amputation. |

**Legend:** CS - case study series; DFO - diabetic foot osteomyelitis; H/CSF - hydroxyapatite and calcium sulfate; PMMA - polymethylmethacrylate; PRP - platelet-rich plasma; RCT - randomized controlled trial; RS - retrospective study; VAC - vacuum assistance.
primary healing in 9 of 15 patients and secondary healing with dressings in a further four. Two patients required transmetatarsal amputation in a mean follow-up of 15 months.

The large case series by Gauland evaluated vancomycin- and gentamicin-loaded calcium sulfate tablets for lower-extremity osteomyelitis in 337 patients [22]. Damaged bone and soft tissues were resected and calcium sulfate tablets were inserted in the dead space. Overall, 86.4% of patients were treated without intravenous antibiotics and 7.4% with intravenous antibiotic administration. The remaining 6.2% was treated with amputation. Furthermore, 70% of patients healed even without oral antibiotic administration.

Melamed and Peled investigated the use of an antibiotic-impregnated cement spacer in 23 cases of foot DFO [23]. Of the 23 cases treated by meticulous debridement and antibiotic-impregnated cement spacer implantation, 21 healed successfully, while the spacer was left permanently in 10 patients. Transfer lesions occurred in one patient only. In two patients, it was necessary to amputate the affected part that did not heal [23].

Walsh and Yates reported that 5 out of 7 Wagner grade 3 ulcers healed with calcanectomy plus gentamicin-impregnated collagen sponge or calcium sulfate with tobramycin [24]. Mean healing time was 64 days (range not stated).

Dalla Paola et al. used vancomycin- and gentamicin-loaded bone cement after surgical debridement with removal of the infected bone for first metatarsalphalangeal DFO [25]. They reported healing in 24 of 28 patients without new ulceration, shoe fit problems, or gait abnormalities. Four patients developed a relapse of the ulceration and one of them underwent percutaneous revascularization and transmetatarsal amputation.

Jogia et al. reported 100% cure in 20 DFO patients who had failed to respond to routine wound debridement, systemic antibiotics, and offloading [26]. Their approach included excision of bone sequestrate and application of biodegradable highly purified synthetic calcium sulfate pellets containing vancomycin and gentamicin. Postoperative systemic antibiotic treatment was decided on an individual basis.

Panagopoulos et al. included 8 patients with chronic metatarsal or calcaneal DFO [3]. These patients were successfully treated with gentamicin delivery either with PMMA cement beads or bone graft substitutes. Local antibiotics were applied after minor surgery in combination with systemic antibiotics. Gentamicin beads were absorbed in ≤2 months without surgical removal. Wound healing was seen in 6 patients.

Elmarsafi et al. evaluated 27 DFO patients treated by PMMA and gentamicin/vancomycin-eluting cement spacers after surgical excisional debridement [27]. Among these patients, 20 spacers were successfully retained or exchanged. Of the 10 patients requiring spacer removal, 4 underwent removal with subsequent arthrodesis and 6 with subsequent pseudoarthrosis, while 8 required ipsilateral partial foot amputation not related to spacer use or removal.

Drampilos et al. successfully treated 12 consecutive patients with calcaneal DFO using bone debridement and local delivery in drilled tunnels of a gentamycin-loaded absorbable calcium sulfate/hydroxyapatite biocomposite [28]. One patient required a subsequent flap operation and 6 needed vacuum-assisted closure. There was also one case of prolonged wound leakage. No major amputation was required.

Niazi et al. evaluated 70 DFO patients treated by debridement, local antibiotic-loaded calcium sulfate/hydroxyapatite bio-composite, and systemic antibiotics based on intra-operative cultures [29]. This treatment resulted in a healing rate of 90%, and there was no recurrence of infection.

4. Discussion and conclusions

DFO remains difficult to treat. Therefore, add-on local antibiotics have been attempted post-operatively to improve outcomes [30]. However, definitive supportive evidence is still rare. In RCTs, gentamicin-impregnated collagen sponge significantly improved clinical cure rates and slightly improved duration of hospitalization. In RSs, antibiotic-impregnated calcium sulfate beads non-significantly improved all healing parameters, but did not reduce post-operative amputation rates or time to healing. The majority of case series used calcium sulfate beads, achieving adequate rates of healing and eradication of infection.

Importantly, there are limitations in available evidence. In fact, only 3 RCTs were identified [15-17]. Further limitations include small patient numbers, wide range of inclusion criteria, heterogeneity of DFO, and the variety of surgical techniques. Accordingly, large rigorously designed RCTs with clear inclusion criteria and procedures are required to shed more light on this issue. Finally, it is still unclear how patients who would most benefit from this add-on therapy can be identified or selected.

In conclusion, add-on local antibiotic delivery following surgery for DFO has achieved some favorable results, mainly healing and eradication rates. Nonetheless, evidence is still limited, while methods and criteria used in the studies have been heterogeneous. Certainly, local antibiotic delivery represents an important step towards improved wound treatment, but more robust evidence is needed, especially on its efficacy in DFO. If its efficacy is finally confirmed, this therapeutic adjunct will certainly enrich our armamentarium for one of the most dangerous diabetic complications [31, 32].

Funding: None.

Conflicts of interest: N. Papanas has been an advisory board member of Astra-Zeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda, and TrigoCare International. He has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GSK, MSD, Novo Nordisk, Novartis, and Sanofi-Aventis and has received honoraria as a speaker for Astra-Zeneca, Boehringer Ingelheim, Eli-Lilly, ELPEN, Galenica, Niazi et al. evaluated 70 DFO patients treated by debridement, local antibiotic-loaded calcium sulfate/hydroxyapatite bio-composite, and systemic antibiotics based on intra-operative cultures [29]. This treatment resulted in a healing rate of 90%, and there was no recurrence of infection.

4. Discussion and conclusions

DFO remains difficult to treat. Therefore, add-on local antibiotics have been attempted post-operatively to improve outcomes [30]. However, definitive supportive evidence is still rare. In RCTs, gentamicin-impregnated collagen sponge significantly improved clinical cure rates and slightly improved duration of hospitalization. In RSs, antibiotic-impregnated calcium sulfate beads non-significantly improved all healing parameters, but did not reduce post-operative amputation rates or time to healing. The majority of case series used calcium sulfate beads, achieving adequate rates of healing and eradication of infection.

Importantly, there are limitations in available evidence. In fact, only 3 RCTs were identified [15-17]. Further limitations include small patient numbers, wide range of inclusion criteria, heterogeneity of DFO, and the variety of surgical techniques. Accordingly, large rigorously designed RCTs with clear inclusion criteria and procedures are required to shed more light on this issue. Finally, it is still unclear how patients who would most benefit from this add-on therapy can be identified or selected.

In conclusion, add-on local antibiotic delivery following surgery for DFO has achieved some favorable results, mainly healing and eradication rates. Nonetheless, evidence is still limited, while methods and criteria used in the studies have been heterogeneous. Certainly, local antibiotic delivery represents an important step towards improved wound treatment, but more robust evidence is needed, especially on its efficacy in DFO. If its efficacy is finally confirmed, this therapeutic adjunct will certainly enrich our armamentarium for one of the most dangerous diabetic complications [31, 32].

Funding: None.

Conflicts of interest: N. Papanas has been an advisory board member of Astra-Zeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Pfizer, Takeda, and TrigoCare International. He has participated in sponsored studies by Astra-Zeneca, Eli-Lilly, GSK, MSD, Novo Nordisk, Novartis, and Sanofi-Aventis and has received honoraria as a speaker for Astra-Zeneca, Boehringer Ingelheim, Eli-Lilly, ELPEN, Galenica, etc.
Takeda, and Vianex. He also attended conferences sponsored by TrigoCare International, Eli-Lilly, Galenica, Novo Nordisk, Pfizer, and Sanofi-Aventis.

**References**

1. Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. *Acta Clin Belg* 2007; 62:230-238.

2. Demetriou M, Papanas N, Panopoulou M, Papaheidodorou K, Bounovas A, Maltezos E. Tissue and swab culture in diabetic foot infections: neuropathic versus neuroischemic ulcers. *Int J Low Extrem Wounds* 2013; 12:87-93.

3. Panagopoulos P, Drosos G, Maltezos E, Papanas N. Local antibiotic delivery systems in diabetic foot osteomyelitis: time for one step beyond? *Int J Low Extrem Wounds* 2015; 14:87-91.

4. Papanas N, Mani, R. Advances in infections and wound healing for the diabetic foot: the die is cast. *Int J Low Extrem Wounds* 2013; 12:83-86.

5. Georgakarakos E, Charalampidis D, Kagakia D, Georgiadis GS, Lazarides MK, Papanas N. Current achievements with topical negative pressure to improve wound healing in dehiscence ischemic stumps of diabetic patients: a case series. *Int J Low Extrem Wounds* 2013; 12:138-145.

6. Wolcott RD, Rhoads DD, Bennett ME, Wolcott BM, Gogokhia L, Costerton JW, Dowd SE. Chronic wounds and the medical biofilm paradigm. *J Wound Care* 2010; 19:45-53.

7. Lipsky BA. Treating diabetic foot osteomyelitis primarily with surgery or antibiotics: have we answered the question? *Diabetes Care* 2014; 37:593-595.

8. Papanas N, Lazarides MK. Diabetic foot amputations in Greece: where do we go from here? *Int J Low Extrem Wounds* 2011; 10:4-5.

9. Edmonds M. Modern treatment of infection and ischaemia to reduce major amputation in the diabetic foot. *Curr Pharm Des* 2013; 19:5008-5015.

10. Lalidou F, Kolios G, Tavriddou A, Drosos GI. Bone grafts as carriers for local antibiotic delivery for the treatment and prevention of bone infections. *Surg Tech Int* 2014; 25:239-245.

11. Downes S, Maughan PA. Mechanism of antibiotic release from poly(methyl methacrylate) bone cement. *Clin Mat* 1989; 4:109-122.

12. Bistolfi A, Massazza G, Verne E, Deledda D, Ferraris S, Miola G, Chatzaki E, Drosos GI. Comparison between commercially available and home-made cement in orthopedic surgery: a review. *Clin Mat* 2011; 290851.

13. Georgakarakos E, Charalampidis D, Kagakia D, Georgiadis GS, Lazarides MK, Papanas N. Current achievements with topical negative pressure to improve wound healing in dehiscence ischemic stumps of diabetic patients: a case series. *Int J Low Extrem Wounds* 2013; 12:138-145.

14. Wolcott RD, Rhoads DD, Bennett ME, Wolcott BM, Gogokhia L, Costerton JW, Dowd SE. Chronic wounds and the medical biofilm paradigm. *J Wound Care* 2010; 19:45-53.

15. Lipsky BA. Treating diabetic foot osteomyelitis primarily with surgery or antibiotics: have we answered the question? *Diabetes Care* 2014; 37:593-595.

16. Papanas N, Lazarides MK. Diabetic foot amputations in Greece: where do we go from here? *Int J Low Extrem Wounds* 2011; 10:4-5.

17. Edmonds M. Modern treatment of infection and ischaemia to reduce major amputation in the diabetic foot. *Curr Pharm Des* 2013; 19:5008-5015.

18. Krause FG, deVries G, Meakin C, Kalla TP, Younger AS. Outcome of transmetatarsal amputations in diabetics using antibiotic beads. *Foot Ankle Int* 2009; 30:486-493.

19. Qin CH, Zhou CH, Song HJ, Cheng GY, Zhang HA, Fang J, Tao R. Infected bone resection plus adjuvant antibiotic-impregnated calcium sulfate versus infected bone resection alone in the treatment of diabetic foot osteomyelitis. *BMC Musculoskelet Disord* 2019; 20:246.

20. Chatzipapas C, Kougioumtzis IE, Karagianni M, Panagopoulos P, Panopoulos M, Papagoloul D, Drosos GJ, Papanas N. Local antibiotic delivery systems in the surgical treatment of diabetic foot osteomyelitis: again, no benefit? *Int J Low Extrem Wounds* 2020; in press.

21. Roukis TS, Schweinberger MH, Schade VL. V-Y fasciocutaneous advancement flap coverage of soft tissue defects of the foot in the patient at high risk. *J Foot Ankle Surg* 2010; 49: 71-74.

22. Gauland C. Managing lower-extremity osteomyelitis locally with surgical debridement and synthetic calcium sulfate antibiotic tablets. *Adv Skin Wound Care* 2011; 24:15-523.

23. Melamed EA, Peled E. Antibiotic impregnated cement spacer for salvage of diabetic osteomyelitis. *Foot Ankle Int* 2012; 133:213-219.

24. Walsh TP, Yates BJ. Calcanectomy: avoiding major amputation in the presence of calcaneal osteomyelitis-A case series. *Foot (Edinb)* 2013; 23:130-135.

25. Dalla Paola L, Carone A, Morisi C, Cardillo S, Pattavina M. Conservative surgical treatment of infected ulceration of the first metatarsophalangeal joint with osteomyelitis in diabetic patients. *J Foot Ankle Surg* 2015; 54:536-540.

26. Joga RI, Modha DE, Nisal K, Berrington R, Kong M-F. Use of highly purified synthetic calcium sulfate impregnated with antibiotics for the management of diabetic foot ulcers complicated by osteomyelitis. *Diabetes Care* 2015; 38:e87-e89.

27. Elmersati T, Oliver NG, Steinberg JS, Evans KK, Attinger CE, Kim PJ. Long-term outcomes of permanent cement spacers in the infected foot. *J Foot Ankle Surg* 2017; 56:287-290.

28. Drampalos E, Mohammad HR, Kosmidis C, Balal M, Wong J, Pillai A. Single stage treatment of diabetic calcaneal osteomyelitis with an absorbable gentamicin-loaded calcium sulphate/hydroxyapatite biocomposite: The Sili technique. *Foot (Edinb)* 2018; 34:40-44.

29. Niazi NS, Drampalos E, Morrissey N, Jahangir N, Wee A, Pillai A. Adjuvant antibiotic loaded bio composite in the management of diabetic foot osteomyelitis - a multicentre study. *Foot (Edinb)* 2019; 39:22-27.

30. Cobb LH, McCabe EM, Priddy LB. Therapeutics and delivery vehicles for local treatment of osteomyelitis. *J Orthop Res* 2020; 38:2091-2103.

31. Demetriou M, Papanas N, Panagopoulos P, Papanolou M, Maltezos E. Atypical microbial isolates from infected diabetic foot ulcers: a case series from Greece. *Rev Diabet Stud* 2017; 14:258-259.

32. Falzon B, Formosa C, Camilleri L, Gatt A. Duration of type 2 diabetes is a predictor of elevated plantar foot pressure. *Rev Diabet Stud* 2018; 14:372-380.
References

1. International Diabetes Federation. IDF diabetes atlas, 9th edition, fact sheet South East Asia, 2020. Available at: http://https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf. Accessed on 21 June 2020.

2. Ahrwar R, Mondal PR. Prevalence of obesity in India: a systematic review. Diabetes Metab Syndr 2019. 13(1):318-321.

3. Wells JC, Pomeroy E, Waimbre SR, Popkin BM, Yajnik CS. The elevated susceptibility to diabetes in India: an evolutionary perspective. Front Public Health 2016. 4:145.

4. Samal KC, Das S, Agarwal BN, Panda NC, Tripathy BB. Nutritional status and profile of NIDDM of recent onset. J Diab Assoc India 1998. 28:99-101.

5. Mohan V, Vijayaprabha R, Rema M, Premalatha G, Poongothai S, Deepa R, Bhatia E, Mackay IR, Zimmet P. Clinical profile of lean NIDDM in South India. Diabetes Res Clin Pract 1997. 38:101-108.

6. Sutjahjo A, Taniguchi H, Hendromartono A, Baba S. High frequency of autonomic as well as peripheral neuropathy in patients with malnutrition-related diabetes mellitus. Diabetes Res Clin Pract 1988. 5:197-200.

7. Garg MK, Tripathy D, Shah P. Patients with malnutrition related diabetes mellitus are as insulin sensitive as insulin dependent diabetics. J Assoc Physicians India 1999. 47:1145-1148.

8. Huh KB, Lee HC, Kim HM, Cho YW, Kim YL, Lee JW, Lee EJ, Lim SK, Kim DH, Yoon JW. Immunogenetic and nutritional profile in insulin-using youth-onset diabetics in Korea. Diabetes Res Clin Pract 1992. 16:63-70.

9. Abu-Bakare A, Taylor R, Gill GV, Alberti KG. Tropical or malnutrition-related diabetes: a real syndrome? Lancet 1986. 1:1135-1138.

10. Unnikrishnan AG, Singh SK, Sanjeevi CB. Prevalence of GAD65 antibodies in lean subjects with type 2 diabetes. Ann N Y Acad Sci 2004. 1037:118-121.

11. American Diabetes Association. Improving care and promoting health in populations: standards of medical care in diabetes 2020. Diabetes Care 2020. 43(Suppl 1):S7-S13.

12. Misra A, Chowhey PC, Makkar BM, Vikram NK, Wasir JS, Chadha D, Joshi SR, Sadikot S, Gupta R, et al. Consensus statement for diagnosis of obesity, Gupta obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009. 57:163-170.

13. Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, Adhikari P, Rao PV, Saboo B, Kumar A, et al. ICMR–INDIAB Collaborative Study Group. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol 2017. 5(8):585-596.

14. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010. 375(9712):408-418.

15. Misra A, Vikram NK, Arya S, Pandey RM, Dhingra V, Chatterjee A, Dwivedi M, Sharma R, Luthra K, Guleria LR, Talwar KK. High prevalence of insulin resistance in postpubertal Asian Indian children is associated with adverse truncal body fat patterning, abdominal adiposity and excess body fat. Int J Obes Relat Metab Disord 2004. 28:1217-1226.

16. Ashraf H, Laway BA, Afroz D, Wani AI. Evaluation of proinflammatory cytokines in obese vs non-obese patients with metabolic syndrome. Indian J Endocrinol Metab 2018. 22:751-756.

17. Balasubramanyam A, Yajnik CS, Tandon N. Non-traditional forms of diabetes worldwide: Implications for translational research. Heliovaara M, Aromaa A, Klaucka T, Knekt P, Joukamaa M, Impivaara O. Reliability and validity of interview data on chronic diseases. The Mini-Finland Health Survey. J Clin Epidemiol 1993. 46:181-191.

18. Ali MK, McKeever Bullard K, Imperatore G, Barker L, Gregg EW, Centers for Disease Control and Prevention. Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes - National Health and Nutrition Examination Survey, United States, 2007-2010. MMWR Suppl 2012. 61(2):32-37.

19. Wexler DJ, Porneala B, Chang Y, Huang ES, Huffman JC, Grant RW. Diabetes differentially affects depression and self-rated health by age in the U.S. Diabetes Care 2012. 35:1575-1577.

20. Caspersen CJ, Thomas GD, Boseman LA, Beckles GL, Albright AL. Aging, diabetes, and the public health system in the United States. Am J Public Health 2012. 102:1482-1497.

21. Ramachandran A, Snehalatha C, Vijay V, King H. Impact of poverty on the prevalence of diabetes and its complications in urban southern India. Diabet Med 2002. 19:130-135.

22. Borgbharkar SS, Das SS. Real-world evidence of glycemic control among patients with type 2 diabetes mellitus in India: the TIGHT study. BMJ Open Diabetes Res Care 2019. 7(1):e000654.